Tesamorelin Peptide
Almost nothing on this shelf ever finished. This one went the entire distance, cleared an FDA approval in 2010, and it was built in Montreal.
Choose your pack
For research use only. Not for human or veterinary use.
What Tesamorelin Peptide is
The plain-language version, first.
Forty-four residues, a full development programme, and a Canadian postcode.
Tesamorelin is a 44 amino acid analogue of human growth hormone releasing hormone, modified at the N-terminus to resist enzymatic breakdown, and it stimulates the pituitary to release growth hormone. It is an approved prescription medicine sold as Egrifta, cleared by the FDA in November 2010 for HIV associated excess abdominal fat, approved by Health Canada but no longer marketed here, and never approved in Europe.
Here's a number that should bother you.
Of everything on this shelf, the count that ran a full development programme, survived every phase, and came out the other side with a regulator's signature is basically one.
This is it. And it came out of Montreal.
Tesamorelin is a 44-residue analogue of GHRH, which is the hormone your hypothalamus sends to tell your pituitary to release growth hormone. Native GHRH is a fragile thing. DPP-4 finds it and cuts it inside minutes.
So the modification is a stabilising group on the N-terminus that stops the enzyme getting a grip.
Theratechnologies took it the whole way and the FDA approved it in 2010, for a specific condition in a specific patient population, under prescription and supervision.
None of which describes what is in this vial, or who is buying it. That approval belongs to a supervised medicine, not to research powder ordered online.
What is tesamorelin?
Mechanism studied, not outcome promised.
It binds the GHRH receptor and prompts your own pituitary to release growth hormone, rather than supplying GH directly. Feedback control and pulsatility are retained.
The approved label requires monitoring IGF-1 during therapy and says to consider discontinuing in patients with persistent elevations.
It doesn't do the job itself. It asks the pituitary to do the job.
Look, there are two ways to raise a signal in a system like this.
You can flood it from outside, or you can go upstream and ask the thing that already makes it to make a bit more.
This is the second kind. It's a message to the pituitary, not a replacement for what the pituitary sends.
That distinction matters more than it sounds. An upstream nudge still runs through the body's own feedback loops, which means the system keeps some say in the outcome.
The engineering problem was never getting GHRH to work. Your body proves it works several times a day. The problem was that GHRH is disposable by design and clears in minutes.
Here's the honest part. Everything above is mechanism, and mechanism is the easy half.
What it produces in a person was studied properly, under supervision, in a population selected for a trial. That is not the same as what happens to anybody who buys powder.
The research so far for Tesamorelin Peptide
Where the evidence is thin, we say so.
A complete development programme, phase 1 through 3, a regulatory submission and an FDA approval in 2010. One of very few peptides to finish the whole route.
Any approval covering research material bought online, or any indication beyond the narrow one granted. The label states its own limitations directly.
Vendors quote the fact of an FDA approval and skip what it was granted for. It covers one narrow indication in one specific patient group, as a supervised prescription product, and the label is unusually explicit about what falls outside that.
The rarest thing in this catalogue: a peptide that made it all the way through.
This one has a real file, and it is worth being precise about what kind of file it is.
A full development programme, phase 1 through 3, a regulatory submission, and an approval granted in 2010.
Which puts it in a category almost nothing else here belongs to.
But read the approval carefully, because vendors love to quote the existence of it and skip the shape of it.
It was granted for one narrow indication, in one specific patient group, as a prescription product with medical oversight. The label is unusually explicit about what it is not approved for, and that sentence exists because people were always going to try.
An approval is a permission granted to a particular product for a particular use. It is not a general endorsement of a molecule, and anybody selling it as one is misreading the document on purpose.
Have a look at current stock and vial sizes.
Tesamorelin Peptide specs
The chemistry, exactly as released.
Who studies Tesamorelin Peptide
Who tends to order this one, and why.
A research compound does not have one audience. It has a handful of rooms where the same question keeps coming up, and the question is a different question in each of them.
HIV medicine
The only indication with pivotal trial evidence, and the population both phase 3 trials enrolled from.
Endocrinology
GHRH receptor pharmacology, pulsatile GH release, and the IGF-1 and glucose consequences of raising the axis.
Body composition research
Visceral adipose tissue by CT scan is the endpoint, which is a different and more specific measurement than body weight or BMI.
Anti-doping laboratories
Tesamorelin is named individually in section S2.2 of the WADA 2026 Prohibited List among growth hormone releasing factors.
Sold for laboratory research only. This is not guidance for personal use, and nothing here is a recommendation.
Tesamorelin Peptide backstory
How it got here.
A specific era of HIV therapy created a specific problem, and for a while there was nothing approved for it.
That is a genuinely unusual position for a drug developer to be in. A defined patient group, a defined problem, and an open field.
Theratechnologies, out of Montreal, built for exactly that. Not a repurposing, not a fishing expedition. A programme aimed at one target.
And it worked, in the sense that matters least to marketing and most to science. It got through.
FDA approval landed in 2010, which makes it one of a very small number of peptide drugs to complete the whole route.
Everything else on this shelf is either older than the regulatory era, or never finished. This one finished.
- 1
A defined problem
A specific era of antiretroviral therapy produced a specific and well-characterised clinical problem, with nothing approved to address it.
- 2
Built in Montreal
Theratechnologies developed the compound for exactly that indication. Not a repurposing and not a fishing expedition, but a programme aimed at one target.
- 3
Stabilised GHRH
Native GHRH is cleared by DPP-4 within minutes. A stabilising group on the N-terminus is what makes a 44-residue analogue usable as a medicine.
- 4
Where it stands
FDA approved in 2010, which makes it one of a very small number of peptide drugs to complete a full development programme through to approval.
Buying Tesamorelin Peptide in Canada
What ships, how fast, and the paperwork.
The hard part of buying research material is almost never the compound. It is the logistics. What leaves the building, how fast it moves, and what is in the box beside the vial. Here is ours, plainly.
Same day out of British Columbia
Our building, our cold packs, our people, and nothing sitting in a customs queue while you refresh a tracking page.
Then into the fridge
Keep it cold and keep it dark. Sealed and freeze-dried it handles a rough trip without ice. Once it lands, fridge.
Weight neutral, per the label
The FDA-approved label states it is not indicated for weight loss management as it has a weight neutral effect. It moves visceral fat. It does not reduce body weight. That is the manufacturer own wording and it is worth knowing before you buy.
Stuff people ask about Tesamorelin Peptide
If your question is not here, email us. Real human answers.
No, and the approved label says so explicitly. Under Limitations of Use it states it is not indicated for weight loss management as it has a weight neutral effect. What the trials measured was visceral adipose tissue by CT scan, which fell 14 to 18 percent, while body weight did not meaningfully change.
Not any more. The 1 milligram product was approved and marketed here from June 2015 and its status changed to cancelled post market on 30 September 2022. The 2 milligram version was cancelled pre-market in July 2023 without ever being marketed. There is no marketed tesamorelin product in Canada today. The cancellation code is sponsor-initiated and does not by itself indicate a safety withdrawal.
The visceral fat comes back. Both phase 3 trials re-randomised patients for a further 26 weeks. Those switched to placebo regained roughly 22 percent in the first study and 16 percent in the second. The effect is entirely dependent on continued dosing.
The application was withdrawn rather than rejected. Ferrer Internacional withdrew the marketing authorisation application on 26 June 2012, and the withdrawal letter states the CHMP considered that the data provided did not allow it to conclude on a positive benefit-risk balance.
GHRH analogues raise growth hormone and therefore IGF-1, and that can worsen glucose tolerance. In the trials, HbA1c of 6.5 percent or higher occurred in 5 percent of tesamorelin patients against 1 percent on placebo, a hazard ratio of 3.3. The label mandates IGF-1 monitoring and states that long-term cardiovascular safety has not been established.
Yes. It is named individually in section S2.2 of the WADA 2026 Prohibited List among growth hormone releasing factors. Section S2 substances are non-specified and prohibited at all times, in and out of competition.
Good pairing options with Tesamorelin Peptide
What researchers stack alongside it.
Pairing is where research gets ahead of itself. These are the compounds researchers put in the same order as Tesamorelin Peptide, which is a statement about ordering habits, not about evidence. Two things in one cart have not been studied together unless somebody studied them together.
The original incretin, exactly as your gut makes it, no edits. Plasma half-life about one minute, which is why every famous analogue exists and why this one is strictly a reference material.
Two different satiety signalling systems in one vial. Which sounds simple until you try to work out which half any given result belongs to.
Order Tesamorelin Peptide right now
One last look before you decide.
Freeze-dried, COA on the page, ships cold
If you are researching Tesamorelin Peptide and you want a source you do not have to second-guess, start with the paperwork on this page. For research use only.
Not for human consumption. Not approved by Health Canada or any other regulatory body.
Page last updated August 19, 2026
People also search for Tesamorelin Peptide
Other names for the same compound.